Exenatide for obesity in children and adolescents: Systematic review and meta-analysis

被引:0
作者
Chen, Bin [1 ,2 ]
Zou, Zhuan [1 ,2 ]
Zhang, Xiaoyan [1 ,2 ]
Xiao, Dongqiong [1 ,2 ]
Li, Xihong [1 ,2 ]
机构
[1] Sichuan Univ, West China Univ Hosp 2, Dept Pediat, Chengdu, Peoples R China
[2] Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Childr, Chengdu, Peoples R China
基金
美国国家科学基金会;
关键词
exenatide; obesity; efficacy; child; meta-analysis; PEPTIDE-1 RECEPTOR AGONISTS; DIABETES-MELLITUS; INSULIN GLARGINE; GLYCEMIC CONTROL; OPEN-LABEL; TYPE-2; LIRAGLUTIDE; EFFICACY; OVERWEIGHT; MANAGEMENT;
D O I
10.3389/fphar.2024.1290184
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: There is no curative treatment for childhood obesity. We aim to synthesize published Randomized Controlled Trials (RCTs) evidence on the efficacy of exenatide in obese children and adolescents. Methods: We conducted a comprehensive search and analysis of relevant studies in popular databases such as PubMed, Web of Science, Embase, and Cochrane Library. Our focus was on RCTs that examined the effectiveness of exenatide for treating obesity in children. We primarily assessed changes in body weight, body mass index (BMI), fasting plasma glucose (FPG), or HbA1c levels. Additionally, we considered any adverse events reported during the treatment period, with particular attention to hypoglycemia. To evaluate the quality of RCTs included in our study, we employed the Cochrane bias assessment tool. Results: Five studies met the inclusion criteria. A group of 100 children were assigned to receive treatment with exenatide. Compared with controls, exenatide therapy reduced body weight and BMI by -0.6% (95% CI -0.93, -0.27), -1.11% (95% CI -1.91, -0.31), respectively. Undesirable consequences encompass gastrointestinal symptoms, with the majority of instances being characterized by mild severity. Conclusion: Exenatide demonstrates efficacy in the treatment of pediatric and adolescent obesity. Systematic Review Registration: PROSPERO https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=413706
引用
收藏
页数:10
相关论文
共 50 条
[1]   Health Effects of Overweight and Obesity in 195 Countries over 25 Years [J].
Afshin, Ashkan ;
Forouzanfar, Mohammad H. ;
Reitsma, Marissa B. ;
Sur, Patrick ;
Estep, Kara ;
Lee, Alex ;
Marczak, Laurie ;
Mokdad, Ali H. ;
Moradi-Lakeh, Maziar ;
Naghavi, Mohsen ;
Salama, Joseph S. ;
Vos, Theo ;
Abate, Kalkidan H. ;
Abbafati, Cristiana ;
Ahmed, Muktar B. ;
Al-Aly, Ziyad ;
Alkerwi, Ala'a ;
Al-Raddadi, Rajaa ;
Amare, Azmeraw T. ;
Amberbir, Alemayehu ;
Amegah, Adeladza K. ;
Amini, Erfan ;
Amrock, Stephen M. ;
Anjana, Ranjit M. ;
Arnlov, Johan ;
Asayesh, Hamid ;
Banerjee, Amitava ;
Barac, Aleksandra ;
Baye, Estifanos ;
Bennett, Derrick A. ;
Beyene, Addisu S. ;
Biadgilign, Sibhatu ;
Biryukov, Stan ;
Bjertness, Espen ;
Boneya, Dube J. ;
Campos-Nonato, Ismael ;
Carrero, Juan J. ;
Cecilio, Pedro ;
Cercy, Kelly ;
Ciobanu, Liliana G. ;
Cornaby, Leslie ;
Damtew, Solomon A. ;
Dandona, Lalit ;
Dandona, Rakhi ;
Dharmaratne, Samath D. ;
Duncan, Bruce B. ;
Eshrati, Babak ;
Esteghamati, Alireza ;
Feigin, Valery L. ;
Fernandes, Joao C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (01) :13-27
[2]   Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor signaling reduces appetitive and motivational aspects of feeding [J].
Alhadeff, Amber L. ;
Grill, Harvey J. .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2014, 307 (04) :R465-R470
[3]   FDA approval of GLP-1 receptor agonist (liraglutide) for use in children [J].
Bacha, Fida .
LANCET CHILD & ADOLESCENT HEALTH, 2019, 3 (09) :595-597
[4]   Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial [J].
Bensignor, Megan O. ;
Bramante, Carolyn T. ;
Bomberg, Eric M. ;
Fox, Claudia K. ;
Hale, Paula M. ;
Kelly, Aaron S. ;
Mamadi, Rashmi ;
Prabhu, Nandana ;
Harder-Lauridsen, Nina M. ;
Gross, Amy C. .
PEDIATRIC OBESITY, 2023, 18 (09)
[5]   Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial [J].
Bergenstal, Richard M. ;
Wysham, Carol ;
MacConell, Leigh ;
Malloy, Jaret ;
Walsh, Brandon ;
Yan, Ping ;
Wilhelm, Ken ;
Malone, Jim ;
Porter, Lisa E. .
LANCET, 2010, 376 (9739) :431-439
[6]   DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes [J].
Blevins, Thomas ;
Pullman, John ;
Malloy, Jaret ;
Yan, Ping ;
Taylor, Kristin ;
Schulteis, Christine ;
Trautmann, Michael ;
Porter, Lisa .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05) :1301-1310
[7]  
Bojanowska E, 2005, MED SCI MONITOR, V11, pRA271
[8]   Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes [J].
Brunton, Stephen ;
Davidson, Jaime A. .
CLINICAL THERAPEUTICS, 2016, 38 (03) :582-594
[9]   Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity [J].
Burcelin, R. ;
Gourdy, P. .
OBESITY REVIEWS, 2017, 18 (01) :86-98
[10]   Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study [J].
Buse, John B. ;
Nauck, Michael ;
Forst, Thomas ;
Sheu, Wayne H-H ;
Shenouda, Sylvia K. ;
Heilmann, Cory R. ;
Hoogwerf, Byron J. ;
Gao, Aijun ;
Boardman, Marilyn K. ;
Fineman, Mark ;
Porter, Lisa ;
Schernthaner, Guntram .
LANCET, 2013, 381 (9861) :117-124